Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia

Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM (1993) The prevalence of prostatism: a population-based survey of urinary symptoms. J.Urol 150:85–89

Chapple C (1998) Pharmacotherapy for benign prostatic hyperplasia- the potential for alpha-1 adrenoceptor subtype-specific blockade. B J Urol 81(1):34–47

Paolone DR (2010) Benign prostatic hyperplasia. Clin Geriatr Med 26(2):223–239

Roehrborn CG, Van Kerrebroeck P, Nordling J (2003) Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo controlled studies. BJU Int 92(3):257–261

Van Kerrebroec P, Jardin A, Van Cangh P, Laval KU, ALFORTI study group (2002) Long term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 41(1):54–60

Chapple C (1996) Selective alpha 1-adrenoceptor antagonist in benign prostatic hyperplasia rationale and clinical experience. Eur Urol 29:129–144

Abrams P, Schulman C, Vaage S (1995) Tamsulosin a selective α1c adrenoceptor antagonist: a randomized controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). Br J Urol 76:325–336

Schulmann CC, Corturiend J, Jonas U, Lock TM, Vaage S, Speakman MJ (1996) Tamsulosin, the first prostate-selective alpha 1 A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29:145–154

Djavan B, Marberger M (1999) A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36:1–13

Buzelin JM, Fonteyne E, Kontturi M, Witjes WP, Khan A (1997) Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostat hyperplasia). The European tamsulosin study group. Br J Urol 80:597–605

Debruyne FM (2000) Alpha blockers: are all created equal? Urology 56(1):20–22

AUA Practice Guidelines Committee (2003) AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170(2):530–547

Kaplan SA, Te AE, Ikeguchi E, Santarosa RP (1997) The treatment of benign prostatic hyperplasia with α blockers in men over age of 80 years. Br J Urol 80:875–879

Janknegt RA, Chapple CR (1993) Efficacy and safety of the α1 blocker doksazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 Studies. Eur Urol 24:319–326

Roehrborn CG (2009) Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol 11(1):1–8

Lapitan MC, Acepcion V, Mangubat J (2005) A comparative study on study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial. J Int Med Res 33(5):562–573

Samli MM, Dinçel Ç (2004) Terazosin and doksazosin in the treatment of BPH: results of a randomized study with crossover in non-responders. Urol Int 73:125–129

Kirby RS (2003) A randomized, double-blind crossover study of tamsulosin and controlled-release doksazosin in patients with benign prostatic hyperplasia. BJU Int 91:41–44

Ikemoto I, Kiyota H, Ohishi O, Abe K, Goto H, Kishimoto K, Miki K (2003) Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drugs crossover study. Int J Urol 10(11):587–594

Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC (1998) Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 159(6):1810–1815

Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N (1999) Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161:2002–2008

Roehrborn CG, Oesterling JE, Olson PJ, Padley RJ (1997) Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT ınvestigator group. Hytrin community assessment trial. Urology 50:556–561

Lepor H (1998) Phase III multicenter placebo controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin investigator group. Urology 51:892–900

McKeage K, Plosker GL (2002) Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once-daily in the management of benign prostatic hyperplasia. Drugs 62:633–653

Michel MC (2007) Alpha 1-adrenoceptors and ejaculatory function. Br J Pharmacol 152(3):289–290